Advanced Biliary Tract Cancer Clinical Trial
Official title:
A Phase II Study of Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib in patients with Immune Checkpoint Inhibitor previously treated advanced biliary tract cancer (BTC).
Recent studies have suggested that local destruction of tumor tissue by cryoablation induced activation and maturation of dendritic cells and tumor-specific T cells by cross-presentation of tumor antigens. While pd-1 blocking antibody interferes with PD-1 mediated T-cell regulatory signaling. And combination of pd-1 blocking antibody plus lenvatinib showed increased ORR in many type of human cancers. Therefore, the objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib in patients with Immune Checkpoint Inhibitor previously treated advanced BTC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05009953 -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05820906 -
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT03358849 -
Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer
|
Phase 1 | |
| Recruiting |
NCT05410197 -
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
|
Phase 2 | |
| Active, not recruiting |
NCT04727996 -
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05823987 -
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
|
Phase 2 | |
| Not yet recruiting |
NCT04733521 -
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04027764 -
Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT04781192 -
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05653180 -
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04005339 -
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
|
Phase 2 | |
| Completed |
NCT04217954 -
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
|
Phase 2 | |
| Recruiting |
NCT05170438 -
Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
|
Phase 2 | |
| Active, not recruiting |
NCT04172402 -
NGS as the First-line Treatment in Advanced Biliary Tract Cancer
|
Phase 2 | |
| Withdrawn |
NCT02597465 -
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
|
Phase 3 | |
| Active, not recruiting |
NCT04969887 -
Combination Immunotherapy in Rare Cancers Under InvesTigation
|
Phase 2 | |
| Recruiting |
NCT04211168 -
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
|
Phase 2 | |
| Recruiting |
NCT05812430 -
Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
|
Phase 2 |